CD274 and urothelial carcinoma: Interestingly, in the IMvigor210 cohort, the high-risk group was linked to a stronger response to anti-PD-L1 immunotherapy, which may be explained by abnormally elevated immune checkpoint gene expression, indicating that the prognostic model can distinguish the efficacy of immunotherapy in urothelial carcinoma.